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Case 1 
GB is a 4 month old male currently living with his aunt.  His 
mother is deceased and nothing is known about the mother’s 
health or the birth history. Over the last 4 weeks, GB devel-
oped worsening watery non-bloody diarrhea and felt warm 
to his caregivers.  Over the last week his oral intake decreased 
significantly; he is being fed formula and phala (soft maize 
porridge).
On examination, GB appears very wasted and is irritable. 
His weight is 2.8 kilograms; his length is 58 centimeters 
which calculates to a weight for height Z score (WHZ) of  
-4.0. His temperature is 34.6 C.  His heart rate is 180/min. 
Respiratory rate is 60/min. His skin hangs loosely and he has 
very little muscle mass.  In his oropharynx he has thick white 
plaques covering his tongue and his mucous membranes are 
dry.  His lungs are clear and he has minimal retractions.  His 
heart exam is notable for a prominent visible heart pulsa-
tions due to his thin body habitus.  There are no appreciable 
murmurs or gallops.  He has good bowel sounds, with a liver 
edge palpable 2 centimeters below the right costal margin 
and a palpable spleen tip.  He also has diffuse lymphaden-
opathy.
The infant is admitted and management is started for his 
malnutrition.  The doctor also orders an HIV test which 
comes back reactive.
Questions for Case 1:
1. Would this presentation be typical for an HIV in-
fected infant? 
2. How can you definitively diagnose HIV infection 
in this child and when should the testing be done? 
3. Does this child qualify for ARV treatment under 
the current guidelines for antiretroviral therapy in 
Malawi?
4. When would you start HIV treatment in this 
child?
5. Is it likely that the child will improve significantly 
with only renourishment?
Case 2 
CD is an 18 month old HIV infected female who has been 
on ARVs for 6 weeks admitted to a nutritional rehabilitation 
unit for the third time in 4 months.  CD has had a fever daily 
for the past 2 weeks and has been coughing for 3 months per 
her mother’s report, and seems to be worsening.  CD has a 
documented weight loss since her discharge 8 weeks earlier 
of  400 grams.  When queried about adherence to ARVs and 
co-trimoxazole, the mother reports 100% adherence and pill 
counts support this.  On exposure history, it is revealed that 
the child’s mother was diagnosed 4 months earlier with smear 
negative tuberculosis (TB) and was started on therapy.  The 
mother has improved on therapy and gained weight.  CD’s 4 
year old sister has also been coughing for 2 months with low 
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grade fevers.  She is also reactive and has been on ARVs for 
1 year and is doing well otherwise.
On examination, CD is very wasted and quite fussy. She 
coughs frequently and forcefully throughout the exam.  Her 
weight is 6 kilograms and her length is 72 cm., with a WHZ 
score of  -3.5. The child has oropharyngeal thrush involving 
the entire mouth and palate. Her lung exam reveals crepita-
tions on the right side.  She also has a candidal infection in 
her vaginal area.  Her liver is 1 centimeter below the right 
costal margin.  The remainder of  her exam is unremarkable.
Given the history and physical findings, the physician orders 
Mantoux testing on both CD and her older sister which are 
read 48 hours after placement.  CD’s test has an induration 
is 10 millimeters while her sister’s was negative with no in-
duration.
Questions for Case 2:
1. Are the Mantoux test results surprising?
2. How would you determine if CD has a latent TB 
infection or active TB disease?
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Discussion of case 1
1. This infant is presenting with severe malnutrition in the 
form of  marasmus.  Children with HIV frequently present 
with wasting and ≥ 50% of  children seeking care for severe 
malnutrition are HIV infected in some sites in sub-Saharan 
Africa.   Marasmus has been the form of  malnutrition most 
associated with HIV infection; however infants and children 
may also present with kwashiorkor or a combination of  
both forms (marasmic kwashiorkor).  Severe malnutrition 
itself  causes a secondary immunodeficiency.
2. The HIV ELISA (antibody) test in the infant less than 
18 months of  age reflects maternal antibodies to HIV 
that have crossed the placenta.  It confirms in utero HIV 
exposure but not infection.  In order to make the diagnosis 
of  HIV infection in the infant you must test the infant to 
see if  he has the virus present in his blood by performing a 
HIV DNA PCR. 
Infants of  reactive mothers should be tested ideally at 6 to 
8 weeks of  age, as HIV infection acquired through the birth 
process should be detectable by that time; this is the mode 
of  infection of  the vast majority of  infants. Breastfeeding is 
another way in which HIV can be transmitted; to confirm 
a negative status, the child must be tested 3 months after 
cessation of  breastfeeding.  For children greater than 18 
months of  age who are not breast feeding, an HIV ELISA 
test can be used as the sole diagnostic test. GB’s PCR result 
was positive.
3. The child in the vignette does qualify for treatment.  It is 
recommended that all infants less than 12 months of  age be 
treated with ARVs because of  the high incidence of  oppor-
tunistic infections and death in young infants with untreated 
HIV.  Aside from age, the patient’s severe malnutrition sta-
tus is also a WHO Clinical Stage 4 finding that would meet 
criteria for treatment as well.  The table below summarizes 
the current guidelines for starting antiretroviral therapy in 
Malawi. Meeting either the CD4 or clinical criteria qualifies 
a child for treatment. Note that in children less than 5 years 
of  age CD4 percentages should be used when evaluating 
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4. HIV treatment should be started as soon as feasible in 
this infant.  The importance of  early treatment of  HIV in 
infants has been demonstrated by the CHER study (Children 
with HIV Early Anti-Retroviral Therapy) performed in 
South Africa and published in late 2008.  This was a study 
of  380 South African infants aged 6 to 12 weeks.  In this 
study, 2/3 the group was randomized to start immediate 
early ART (i.e. while essentially asymptomatic) while the 
other 1/3 was randomized to a deferred therapy per WHO 
clinical guidelines. They found a 76% reduction in mortality 
in the early treatment group through 15 months of  age as 
well as a 75% reduction in progression in clinical stage of  
the infants’ HIV disease. Overall, the infants tolerated ARVs 
well. For malnourished children, there is not as much data 
on ARV start but the data that exists strongly supports early 
treatment.  This is an area that merits further study.
5. It is not likely that the child will improve on renourishment 
alone. In studies done on nutritional rehabilitation programs, 
HIV non-reactive infants have been shown to have 
significantly better survival compared with their HIV infected 
peers.  Strong evidence supports that recovery in these 
children is dependent on timely nutritional rehabilitation and 
ARV therapy.
AGE <12 Months 1-3 Years 3-5 Years >5 Years of age
CD4 Criteria 
(% or absolute count)
All infants should be 
treated regardless of CD4 
or clinical criteria
≤ 20% ≤ 15% ≤ 15% or absolute CD4 
count of 250
Clinical Criteria WHO Clinical Stage 3 or 4 WHO Clinical Stage 3 or 4 WHO Clinical Stage 3 or 4
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Discussion of Case 2
1. The Mantoux results, though inconsistent between 
the sisters, are not surprising.  Mantoux testing in the 
immunocompromised child can be quite unreliable due 
to anergy, therefore a negative Mantoux does not rule 
out active TB infection in these children. Children with 
disseminated or miliary TB are also often Mantoux negative. 
CD’s positive Mantoux test given her level of  immune 
suppression is strongly suggestive of  TB infection in this 
immunocompromised child.
2. The positive Mantoux test confirms that CD is infected 
with TB.  To determine if  CD has active TB disease, we 
must review her symptoms as well as obtain a chest x-ray 
(CXR).  Even if  the CXR were negative, given CD’s poor 
immune status and consistent symptoms, she meets a clinical 
diagnosis of  active TB infection and should be treated 
accordingly (see answer 5).  If  she were a well asymptomatic 
child with a negative CXR, the diagnosis would be latent TB 
infection and prophylaxis with 6 months of  isoniazid would 
be indicated.
3. Chest X-ray findings in tuberculosis can be quite varied, 
ranging from paratracheal and hilar adenopathy to atelectasis 
of  lobes (from airway compression from adenopathy) to 
a widened mediastinum to parenchymal findings. Other 
findings include a diffuse or miliary pattern (often described 
as a snow storm appearance), pleural effusions, and 
cardiomegaly (in the case of  TB pericarditis with effusion). 
It is rare that children develop the cavitary disease seen in 
adults, but can be seen in adolescents; they are usually thin 
walled in appearance on CXR.  Fortunately, young infants 
and children are not highly contagious for TB because of  the 
absence of  cavitation and weak cough. 
Chest X-ray showing bilateral perihilar lymphadenopathy, widening of 
mediastinum and splaying of the carina.
4. Though much is made of  the highly contagious nature of  
sputum positive TB, it should be realized that sputum negative 
TB is far more prevalent and likely accounts for many more 
secondary infections. In one model of  TB infection patterns 
it is estimated that smear positive individuals are 6 times 
more likely to transmit the infection to others. However, the 
ratio of  smear negative to smear positive individuals in the 
population is estimated to be 35 to 1.
5. Standard therapy for treatment of  pulmonary TB in 
Malawi includes the drugs Isoniazid (H), Rifampicin (R), 
Pyrazinamide (Z) and Ethambutol (E).  For sputum positive 
TB, treatment is with RHZE 3 times weekly for 2 months 
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followed by EH daily for 6 months.  For sputum negative TB, 
RHZ is used for the initial phase. Sputum is often difficult 
to obtain from young children, but it should be attempted 
to try to determine sputum status as well as attempting to 
grow the bacteria so that it may be tested for susceptibilities 
if  indicated.  Another approach is to obtain sputum from 
the patient’s mother or symptomatic adults who care for the 
child.
To recover, both TB treatment and ARVs are needed. 
Treating the TB first may decrease the likelihood of  immune 
reconstitution syndrome (see answer 6).  If  TB treatment is 
started prior to ARVs, the TB drugs should be allowed to 
attain steady state.  Old recommendations were to wait at 
least 2 months before starting ARVs; however, this timetable 
may be able to be moved up to starting ARVs 2 to 4 weeks 
after TB treatment in select severely immunocompromised 
children in need of  urgent ARV therapy.  
Rifampicin interacts with nevirapine, one of  the three 
drugs given in the ARV regimen.  Rifampicin increases the 
metabolism of  nevirapine, resulting in lowered nevirapine 
levels.  Because of  this, children on TB therapy who are 
starting ARVs should start on full dose nevirapine and not 
the initial 2 week lead in of  half  dose nevirapine that is 
standardly done in patients not on TB therapy.
6.CD’s course is suggestive of  Immune Reconstitution 
Inflammatory Syndrome, abbreviated as IRIS. IRIS is 
seen in severely immunocompromised individuals who 
achieve immunological recovery be it from ARV therapy, 
improvement in severe malnutrition, or discontinuation 
of  medicines that suppress the immune system.  In their 
suppressed immunologic state, patients often have
smoldering infections that have not clearly demonstrated 
themselves due to the absence of  inflammation which would 
normally be caused by a healthy immune system.  When 
the immune system recovers, it then sees these infections 
and attacks them exuberantly, resulting in a potentially 
overwhelming inflammatory state.  
IRIS has been described in patients who have been on 
ARVs for weeks to months, although it is usually seen on 
the earlier end of  this spectrum.  Other infections with 
which IRIS can be seen include Pneumocystis pneumonia, 
cryptococcal meningitis, and hepatitis. Unfortunately, in the 
severely suppressed patient, distinguishing between IRIS and 
a new serious infection is difficult; IRIS must be considered 
a diagnosis of  exclusion.  Further work to define consistent 
clinical criteria to define IRIS is needed.
